{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:37:14Z","timestamp":1763429834227,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clgc.2022.10.011","type":"journal-article","created":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T19:44:58Z","timestamp":1666554298000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-5162","authenticated-orcid":false,"given":"Tiago Costa de","family":"Padua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Hallanger-Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kutikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.10.011_bib0001","doi-asserted-by":"crossref","first-page":"636","DOI":"10.14740\/jocmr3503w","article-title":"The characteristics and trends in adrenocortical carcinoma: a united states population based study","volume":"10","author":"Sharma","year":"2018","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.clgc.2022.10.011_bib0002","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0003","series-title":"Proc Natl Acad Sci U S A.","first-page":"9330","article-title":"An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma","volume":"98","author":"Ribeiro","year":"2001"},{"key":"10.1016\/j.clgc.2022.10.011_bib0004","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clgc.2022.10.011_bib0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.clgc.2022.10.011_bib0006","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2022.10.011_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2022.40.6_suppl.001","article-title":"First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study","volume":"40","author":"Berruti","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0008","first-page":"1006","article-title":"Eastern cooperative oncology group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma","volume":"110","author":"Decker","year":"1991","journal-title":"Surgery"},{"key":"10.1016\/j.clgc.2022.10.011_bib0009","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3","article-title":"Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer","volume":"83","author":"Berruti","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0010","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R","article-title":"Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest oncology group study","volume":"88","author":"Williamson","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0011","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/annonc\/mdf291","article-title":"Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma","volume":"13","author":"Baudin","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0012","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0013","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0015","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clgc.2022.10.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100422","article-title":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","volume":"7","author":"Lagan\u00e0","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2022.10.011_bib0017","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"British J Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0019","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2022.10.011_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 Blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0022","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1908771","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538","volume":"10","author":"Klein","year":"2021","journal-title":"Oncoimmunology"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2022.10.011_bib0023","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1200\/JCO.2022.40.16_suppl.4596","article-title":"EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study","volume":"40","author":"Baudin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0024","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10637-020-00899-1","article-title":"A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma","volume":"38","author":"Smith","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2022.10.011_bib0025","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2022.10.011_bib0026","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0027","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2022.10.011_bib0028","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1200\/jco.2014.32.15_suppl.4588","article-title":"Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03","volume":"32","author":"Garc\u00eda-Donas","year":"2014","journal-title":"J Cli Oncol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0029","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0030","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2022.10.011_bib0031","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.10.011_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9362108","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clgc.2022.10.011_bib0033","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.clgc.2022.10.011_bib0034","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Nat Comprehens Cancer Network"},{"key":"10.1016\/j.clgc.2022.10.011_bib0036","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Euro J Endocrinol"},{"key":"10.1016\/j.clgc.2022.10.011_bib0037","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","article-title":"Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy","volume":"38","author":"Bednarski","year":"2014","journal-title":"World J Surg"},{"key":"10.1016\/j.clgc.2022.10.011_bib0038","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2022.10.011_bib0039","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2022.10.011_bib0040","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/oncolo\/oyac061","article-title":"Blood-based next-generation sequencing in adrenocortical carcinoma","volume":"27","author":"Nazha","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2022.10.011_bib0041","unstructured":"KEYTRUDA Highlights of prescribing information. Accessed September 30, 2022 from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125514s014lbl.pdf."},{"key":"10.1016\/j.clgc.2022.10.011_bib0042","unstructured":"LAROTRECTINIB Highlights of prescribing information. Accessed September, 30, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211710s000lbl.pdf"},{"key":"10.1016\/j.clgc.2022.10.011_bib0043","unstructured":"FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. Retrieved September, 30, 2022 from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid"},{"key":"10.1016\/j.clgc.2022.10.011_bib0044","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.eururo.2021.12.025","article-title":"A point-of-care resource to improve care of patients with adrenal mass: www.AdrenalMass.org","volume":"81","author":"Strother","year":"2022","journal-title":"Eur Urol."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732200218X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732200218X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:38:04Z","timestamp":1761565084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732200218X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S155876732200218X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.10.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}